M1 KLINIKEN AG (M12.DE) Fundamental Analysis & Valuation

FRA:M12 • DE000A0STSQ8

Current stock price

15.4 EUR
+0.58 (+3.91%)
Last:

This M12.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. M12.DE Profitability Analysis

1.1 Basic Checks

  • In the past year M12 was profitable.
  • In the past year M12 had a positive cash flow from operations.
  • In the past 5 years M12 has always been profitable.
  • In the past 5 years M12 always reported a positive cash flow from operatings.
M12.DE Yearly Net Income VS EBIT VS OCF VS FCFM12.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M

1.2 Ratios

  • The Return On Assets of M12 (8.73%) is better than 96.43% of its industry peers.
  • With an excellent Return On Equity value of 15.03%, M12 belongs to the best of the industry, outperforming 85.71% of the companies in the same industry.
  • M12's Return On Invested Capital of 13.44% is amongst the best of the industry. M12 outperforms 92.86% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for M12 is in line with the industry average of 6.23%.
  • The last Return On Invested Capital (13.44%) for M12 is above the 3 year average (7.72%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 8.73%
ROE 15.03%
ROIC 13.44%
ROA(3y)5.18%
ROA(5y)4.73%
ROE(3y)9.59%
ROE(5y)9.22%
ROIC(3y)7.72%
ROIC(5y)6.16%
M12.DE Yearly ROA, ROE, ROICM12.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

  • With a decent Profit Margin value of 5.00%, M12 is doing good in the industry, outperforming 75.00% of the companies in the same industry.
  • In the last couple of years the Profit Margin of M12 has declined.
  • With a decent Operating Margin value of 8.52%, M12 is doing good in the industry, outperforming 71.43% of the companies in the same industry.
  • M12's Operating Margin has declined in the last couple of years.
  • M12 has a worse Gross Margin (19.29%) than 60.71% of its industry peers.
  • M12's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 8.52%
PM (TTM) 5%
GM 19.29%
OM growth 3Y27.08%
OM growth 5Y-5.31%
PM growth 3Y18.61%
PM growth 5Y-17.82%
GM growth 3Y2.18%
GM growth 5Y-14.45%
M12.DE Yearly Profit, Operating, Gross MarginsM12.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. M12.DE Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), M12 is creating value.
  • Compared to 1 year ago, M12 has less shares outstanding
  • The number of shares outstanding for M12 has been increased compared to 5 years ago.
  • The debt/assets ratio for M12 is higher compared to a year ago.
M12.DE Yearly Shares OutstandingM12.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
M12.DE Yearly Total Debt VS Total AssetsM12.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • M12 has an Altman-Z score of 5.35. This indicates that M12 is financially healthy and has little risk of bankruptcy at the moment.
  • M12's Altman-Z score of 5.35 is amongst the best of the industry. M12 outperforms 96.43% of its industry peers.
  • The Debt to FCF ratio of M12 is 0.70, which is an excellent value as it means it would take M12, only 0.70 years of fcf income to pay off all of its debts.
  • M12 has a better Debt to FCF ratio (0.70) than 100.00% of its industry peers.
  • M12 has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of M12 (0.05) is better than 96.43% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF 0.7
Altman-Z 5.35
ROIC/WACC1.81
WACC7.43%
M12.DE Yearly LT Debt VS Equity VS FCFM12.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M 100M

2.3 Liquidity

  • A Current Ratio of 2.06 indicates that M12 has no problem at all paying its short term obligations.
  • M12's Current ratio of 2.06 is amongst the best of the industry. M12 outperforms 89.29% of its industry peers.
  • A Quick Ratio of 1.35 indicates that M12 should not have too much problems paying its short term obligations.
  • M12 has a better Quick ratio (1.35) than 78.57% of its industry peers.
Industry RankSector Rank
Current Ratio 2.06
Quick Ratio 1.35
M12.DE Yearly Current Assets VS Current LiabilitesM12.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. M12.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 10.36% over the past year.
  • The Earnings Per Share has been growing slightly by 7.97% on average over the past years.
  • Looking at the last year, M12 shows a small growth in Revenue. The Revenue has grown by 6.52% in the last year.
  • M12 shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 34.44% yearly.
EPS 1Y (TTM)10.36%
EPS 3Y21.62%
EPS 5Y7.97%
EPS Q2Q%25%
Revenue 1Y (TTM)6.52%
Revenue growth 3Y2.54%
Revenue growth 5Y34.44%
Sales Q2Q%9.42%

3.2 Future

  • Based on estimates for the next years, M12 will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.27% on average per year.
  • The Revenue is expected to grow by 8.24% on average over the next years. This is quite good.
EPS Next Y9.46%
EPS Next 2Y12.44%
EPS Next 3Y12.27%
EPS Next 5YN/A
Revenue Next Year5.17%
Revenue Next 2Y6.28%
Revenue Next 3Y6.07%
Revenue Next 5Y8.24%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
M12.DE Yearly Revenue VS EstimatesM12.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
M12.DE Yearly EPS VS EstimatesM12.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.2 0.4 0.6 0.8 1

More info and screens

Find the best growth stocksShow best growing peers

5

4. M12.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 16.38, M12 is valued correctly.
  • M12's Price/Earnings is on the same level as the industry average.
  • M12's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.66.
  • With a Price/Forward Earnings ratio of 13.83, M12 is valued correctly.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of M12 indicates a somewhat cheap valuation: M12 is cheaper than 64.29% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of M12 to the average of the S&P500 Index (38.00), we can say M12 is valued rather cheaply.
Industry RankSector Rank
PE 16.38
Fwd PE 13.83
M12.DE Price Earnings VS Forward Price EarningsM12.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • 64.29% of the companies in the same industry are more expensive than M12, based on the Enterprise Value to EBITDA ratio.
  • M12's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 11.33
EV/EBITDA 7.42
M12.DE Per share dataM12.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • M12 has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as M12's earnings are expected to grow with 12.27% in the coming years.
PEG (NY)1.73
PEG (5Y)2.06
EPS Next 2Y12.44%
EPS Next 3Y12.27%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. M12.DE Dividend Analysis

5.1 Amount

  • M12 has a Yearly Dividend Yield of 3.33%. Purely for dividend investing, there may be better candidates out there.
  • M12's Dividend Yield is rather good when compared to the industry average which is at 1.84. M12 pays more dividend than 89.29% of the companies in the same industry.
  • M12's Dividend Yield is rather good when compared to the S&P500 average which is at 1.81.
Industry RankSector Rank
Dividend Yield 3.33%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years1
M12.DE Yearly Dividends per shareM12.DE Yearly Dividends per shareYearly Dividends per share 2018 2019 2024 2025 0.1 0.2 0.3 0.4

5.3 Sustainability

DPN/A
EPS Next 2Y12.44%
EPS Next 3Y12.27%
M12.DE Yearly Income VS Free CF VS DividendM12.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

More info and screens

Find the best dividend stocksShow peers with best dividend

M12.DE Fundamentals: All Metrics, Ratios and Statistics

M1 KLINIKEN AG

FRA:M12 (4/21/2026, 7:00:00 PM)

15.4

+0.58 (+3.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-18
Earnings (Next)04-22
Inst Owners1.07%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap302.46M
Revenue(TTM)354.98M
Net Income(TTM)17.74M
Analysts85.71
Price Target28.05 (82.14%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 3.33%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)4.06%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.87%
Valuation
Industry RankSector Rank
PE 16.38
Fwd PE 13.83
P/S 0.85
P/FCF 11.33
P/OCF 11.18
P/B 2.56
P/tB 11.01
EV/EBITDA 7.42
EPS(TTM)0.94
EY6.1%
EPS(NY)1.11
Fwd EY7.23%
FCF(TTM)1.36
FCFY8.83%
OCF(TTM)1.38
OCFY8.94%
SpS18.07
BVpS6.01
TBVpS1.4
PEG (NY)1.73
PEG (5Y)2.06
Graham Number11.2725 (-26.8%)
Profitability
Industry RankSector Rank
ROA 8.73%
ROE 15.03%
ROCE 19.39%
ROIC 13.44%
ROICexc 18.99%
ROICexgc 105.66%
OM 8.52%
PM (TTM) 5%
GM 19.29%
FCFM 7.52%
ROA(3y)5.18%
ROA(5y)4.73%
ROE(3y)9.59%
ROE(5y)9.22%
ROIC(3y)7.72%
ROIC(5y)6.16%
ROICexc(3y)9.69%
ROICexc(5y)8.26%
ROICexgc(3y)31.7%
ROICexgc(5y)24.88%
ROCE(3y)11.15%
ROCE(5y)8.88%
ROICexgc growth 3Y38.16%
ROICexgc growth 5Y31.27%
ROICexc growth 3Y22.22%
ROICexc growth 5Y5.12%
OM growth 3Y27.08%
OM growth 5Y-5.31%
PM growth 3Y18.61%
PM growth 5Y-17.82%
GM growth 3Y2.18%
GM growth 5Y-14.45%
F-Score9
Asset Turnover1.75
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF 0.7
Debt/EBITDA 0.17
Cap/Depr 6.62%
Cap/Sales 0.1%
Interest Coverage 21.13
Cash Conversion 76.34%
Profit Quality 150.51%
Current Ratio 2.06
Quick Ratio 1.35
Altman-Z 5.35
F-Score9
WACC7.43%
ROIC/WACC1.81
Cap/Depr(3y)22.84%
Cap/Depr(5y)24.89%
Cap/Sales(3y)0.41%
Cap/Sales(5y)0.51%
Profit Quality(3y)272.44%
Profit Quality(5y)207.18%
High Growth Momentum
Growth
EPS 1Y (TTM)10.36%
EPS 3Y21.62%
EPS 5Y7.97%
EPS Q2Q%25%
EPS Next Y9.46%
EPS Next 2Y12.44%
EPS Next 3Y12.27%
EPS Next 5YN/A
Revenue 1Y (TTM)6.52%
Revenue growth 3Y2.54%
Revenue growth 5Y34.44%
Sales Q2Q%9.42%
Revenue Next Year5.17%
Revenue Next 2Y6.28%
Revenue Next 3Y6.07%
Revenue Next 5Y8.24%
EBIT growth 1Y32.15%
EBIT growth 3Y30.31%
EBIT growth 5Y27.31%
EBIT Next Year39.44%
EBIT Next 3Y18.54%
EBIT Next 5YN/A
FCF growth 1Y132.58%
FCF growth 3Y27.23%
FCF growth 5YN/A
OCF growth 1Y108.94%
OCF growth 3Y24.88%
OCF growth 5YN/A

M1 KLINIKEN AG / M12.DE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for M1 KLINIKEN AG?

ChartMill assigns a fundamental rating of 6 / 10 to M12.DE.


What is the valuation status for M12 stock?

ChartMill assigns a valuation rating of 5 / 10 to M1 KLINIKEN AG (M12.DE). This can be considered as Fairly Valued.


Can you provide the profitability details for M1 KLINIKEN AG?

M1 KLINIKEN AG (M12.DE) has a profitability rating of 6 / 10.


Can you provide the expected EPS growth for M12 stock?

The Earnings per Share (EPS) of M1 KLINIKEN AG (M12.DE) is expected to grow by 9.46% in the next year.